MPG.eBooks - Search Results

1

CADTH Canadian Drug Expert Committee recommendation: Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemi...

Published 2018

CADTH

Subjects: “...Drug Costs...”

Read Now

2

CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

3

CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

4

CADTH Canadian Drug Expert Committee final recommendation: Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

5

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

6

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

7

CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

8

Pharmacoeconomic review report: Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Costs and Cost Analysis...”

Read Now

9

CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

10

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Drug Costs...”

Read Now

11

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

12

CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

13

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

14

CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary ty...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

15

CADTH Canadian Drug Expert Committee final recommendation: Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

16

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

17

CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Read Now

18

CADTH Canadian Drug Expert Committee recommendation: Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease

Published 2018

CADTH

Subjects: “...Drug Costs...”

Read Now

19

CADTH Canadian Drug Expert Committee final recommendation: Emtricitabine / tenofovir alafenamide (Descovy -- Gilead Sciences Canada, Inc.) indication : HIV-1 infection

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Drug Costs...”

Read Now

20

CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Cost-Benefit Analysis...”

Narrow Search